Kloft C - Search Results

1

Safety of therapeutic monoclonal antibodies.

Niebecker R, Kloft C. Niebecker R, et al. Among authors: kloft c. Curr Drug Saf. 2010 Oct;5(4):275-86. doi: 10.2174/157488610792246055. Curr Drug Saf. 2010. PMID: 20615177 Review.

2

Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Edlund H, Melin J, Parra-Guillen ZP, Kloft C. Edlund H, et al. Among authors: kloft c. Clin Pharmacokinet. 2015 Jan;54(1):35-80. doi: 10.1007/s40262-014-0208-4. Clin Pharmacokinet. 2015. PMID: 25516414 Review.

3

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.

Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A, Karlsson MO. Kloft C, et al. Invest New Drugs. 2004 Jan;22(1):39-52. doi: 10.1023/b:drug.0000006173.72210.1c. Invest New Drugs. 2004. PMID: 14707493

4

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development.

Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C. Kuester K, et al. Among authors: kloft c. Br J Cancer. 2008 Mar 11;98(5):900-6. doi: 10.1038/sj.bjc.6604265. Epub 2008 Mar 4. Br J Cancer. 2008. PMID: 18319714 Free PMC article.

5

Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C. Kuester K, et al. Among authors: kloft c. Clin Pharmacokinet. 2009;48(7):477-87. doi: 10.2165/11313400-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19691369

6

In vitro pharmacodynamic models to determine the effect of antibacterial drugs.

Gloede J, Scheerans C, Derendorf H, Kloft C. Gloede J, et al. Among authors: kloft c. J Antimicrob Chemother. 2010 Feb;65(2):186-201. doi: 10.1093/jac/dkp434. Epub 2009 Dec 21. J Antimicrob Chemother. 2010. PMID: 20026612 Review.

7

[Medication safety in hospitals].

Sleinitz A, Heyde C, Kloft C. Sleinitz A, et al. Among authors: kloft c. Med Monatsschr Pharm. 2012 Apr;35(4):140-51. Med Monatsschr Pharm. 2012. PMID: 22582518 Review. German.

8

Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Mueller-Schoell A, et al. Among authors: kloft c. Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8. Epub 2020 Nov 9. Eur J Clin Pharmacol. 2021. PMID: 33165648 Free PMC article. Review.

9

Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies.

Montefusco-Pereira CV, Carvalho-Wodarz CS, Seeger J, Kloft C, Michelet R, Lehr CM. Montefusco-Pereira CV, et al. Among authors: kloft c. Drug Discov Today. 2021 Jan;26(1):148-163. doi: 10.1016/j.drudis.2020.10.016. Epub 2020 Nov 21. Drug Discov Today. 2021. PMID: 33232842 Review.

10

[Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].

Schwalbe O, Wunderlich S, Kloft C. Schwalbe O, et al. Among authors: kloft c. Med Monatsschr Pharm. 2006 Jun;29(6):222-4. Med Monatsschr Pharm. 2006. PMID: 16792199 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

211 results

Search Page